ÌÇÐÄvlog´«Ã½

Europe Regenerative Medicines Market Analysis

The Europe Regenerative Medicines market is expected to grow with a CAGR of 6.4% over the forecast period, (2022-2027)

The outbreak of the COVID-19 pandemic is anticipated to have a significant impact on the regenerative medicines market in Europe. According to the research article published by European Respiratory Journal in June 2020, titled ''Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19, novel therapeutic approaches such as cell-based therapies, especially using mesenchymal stem cells were found to have demonstrated the safety and efficacy in providing effective treatment in patients with acute respiratory distress syndrome (ARDS). Thus, there has been an increasing focus on developing stem cell-based therapies in treating SARS-CoV-2 viral infection. Thus, owing to the aforementioned factors, the studied market is expected to witness a significant impact during the pandemic.

The key factors propelling the growth of the regenerative medicines market in Europe are the increasing adoption of stem-cell technologies, gene therapies, and tissue engineering, and the technological advancements in regenerative medicines.

According to the clinical trial registry as of August 26th, 2022, there were 1,868 clinical trials of stem cell therapy, of which 82 studies were specifically targeted toward regenerative medicines across the world. This is likely to increase the demand for stem cell-based products and regenerative medicines in the market over the next few years. According to the clinicaltrials.gov database, the majority of active recruiting trials are present in Europe. Acute lymphoblastic leukemia (ALL), acute megakaryoblastic leukemia (AML), and acute graft versus host disease (AGHD) are some of the current indications that are primarily being focused upon by the majority of the universities, research centers, and companies. Thus, it is evident that there are growing initiatives associated with stem cells and regenerative medicines, and it is estimated that over the forecast period, the success rate and further approval will rise gradually, which is primarily expected to drive the growth of the market.

Furthermore, according to the United Nations Population Fund's World Population Dashboard's Statistics 2021, Italy has approximately 23.8% of the population aged 65 and above. Thus, the increasing aging population is prone to chronic diseases as a result, demand for regenerative medicines is predicted to rise over the forecast period.

Moreover, as per the article published in August 2022, titled ''European first as County Durham stroke patient, 28, takes part in stem cell treatment trial, a young patient from County Durham is the first in Europe to take part in a new trial to discover whether stem cell treatment can improve recovery from strokes. Such instances are expected to increase the demand for cell therapy, thereby, boosting the growth of the market over the forecast period.

However, regulatory and ethical issues and the high cost of treatments are expected to hinder the growth of the market.

Europe Regenerative Medicines Industry Segmentation

As per the scope of this report, regenerative medicines are used to repair, replace, and regenerate the tissues and organs affected by injury, disease, or the natural aging process. These medicines restore the functionality of cells and tissues and are used in several degenerative disorders, such as dermatology, neurodegenerative diseases, cardiovascular, and orthopedic applications. The Europe Regenerative Medicines market is segmented by Type of Technology, Application, and Geography. By Type of Technology, the market is segmented into Stem Cell Therapy, Biomaterial, Tissue Engineering, and Other Types of Technologies. By Application, the market is segmented into Bone Graft Substitutes, Osteoarticular Diseases, Dermatology, Cardiovascular, Central Nervous System, and Other Applications. By Geography, the market is segmented into Germany, United Kingdom, France, Italy, Spain, and Rest of Europe. The report offers the value (in USD million) for the above segments.